EMulate Therapeutics Inc. (EMTx) Announces Company Presentation at Life Sciences Innovation North-West 2023 Low to ultra-low radio frequency energy signals (ulRFE®) are the basis of the new digital therapeutic innovation by EMTx BELLEVUE, Wash., April 18, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, a...

EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors BELLEVUE, Wash., March 14, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, Inc. (“EMulate” or the “Company”) a clinical-stage company, developing digital medicines that are safe, non-invasive, and...

EMulate Therapeutics Announces the Publication of Positive Pre-clinical Data Evaluating Pain Reduction via Delivery of Low and Ultra-low Radio Frequency Energy BELLEVUE, Wash., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EMulate Therapeutics, a clinical-stage, life sciences, digital therapeutics company developing safe, non-invasive, and highly effective treatments...

EMulate Therapeutics Forms Technology Advisory Committee to Promote Growth and Innovation BELLEVUE, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- EMulate Therapeutics, a clinical-stage, life sciences, bio-electronics company developing safe, non-invasive, and highly effective treatments for...